Biolase Technology (BIOL) 2.22 $BIOL
Biolase CFO bids adieu
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:14PM CST
BIOL: 2.22 (+0.22)
BIOLASE Announces Management Change
Business Wire - Fri Feb 06, 3:05PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported that Frederick D. Furry has resigned as Chief Financial Officer, effective January 31, 2015 to pursue other opportunities.
BIOL: 2.22 (+0.22)
UPDATE - Ebola and Other Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 1:43PM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.22 (+0.22)
Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 10:48AM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.22 (+0.22)
Medical Laser Systems - 2014 Global Strategic Business Report
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/q7pvtt/medical_laser) has announced the addition of the "Medical Laser Systems - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Medical Laser Systems in US$ Million by the following Product Segments: - Surgical Lasers - Aesthetic Lasers - Ophthalmic Lasers - Diagnostic Lasers - Therapeutic Lasers - Accessories & Services The report profiles 119 companies including many key and niche players such as: - AngioDynamics, Inc. - Bausch & Lomb Incorporated - BIOLASE, Inc. - Biolitec AG - Cardiogenesis Corporation Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Market Trends And Issues 3. Medical Laser Systems: Product Overview 4. Product Introductions/Approvals 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 119 (including Divisions/Subsidiaries 145) - The United States (70) - Canada (3) - Japan (6) - Europe (53) - France (4) - Germany (22) - The United Kingdom (4) - Italy (7) - Spain (1) - Rest of Europe (15) - Asia-Pacific (Excluding Japan) (10) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/q7...ical_laser
BIOL: 2.22 (+0.22)
Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020
M2 - Tue Dec 16, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcpwzv/global_dental) has announced the addition of the "Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020" report to their offering. The global dental market comprises dental implants, dental prosthesis, dental biomaterials, dental crowns and bridges, dental imaging, dental units and equipment. In the past decade, the market has experienced a swelling expansion due to a surge in the uptake of implants, crowns and cosmetic dentistry. The key factors igniting the market growth include poor oral hygiene, a rise in incidences of oral diseases on the back of a growing elderly population, an improvement in oral care needs of individuals and an increasing disposable income in developing economies. The acceptance and proliferation of technology in terms of dental imaging (3D imaging), design and manufacturing (CAD/CAM) has resulted in better diagnosis, dental designs, patient compliance and a decrease in chair time. Globally, the US is the leading market for dental care devices with its Centers for Medicare and Medicaid Services (CMS) having estimated the demand for dental services in the country to approach $167 billion by 2015. As per The Association of Dental Dealers of Europe (ADEE), in 2011, the European dental market increased by 1.2% in terms of the total turnover for all countries with the number of active dentists increasing slightly by 0.8%. Another key market is the Asia-Pacific region. Japan is a relatively mature market in the APAC region, whereas in developing countries like India and China, rising disposable income of the middle class as well as growing dental-care awareness and consumer acceptance are contributing to market growth. Companies Mentioned - A-Dec Inc. - Biolase Inc. - Danaher Corporation - GC CORPORATION - Henry Schein Inc. - Midmark Corporation - NAKANISHI INC. - Nobel Biocare - Patterson Dental Supply Inc. - Planmeca Oy - Sirona Dental Systems Inc. - Straumann (SIX) - Sybron Dental Specialties Inc. - Young Innovations Inc. For more information visit http://www.researchandmarkets.com/research/tc...bal_dental
SIRO: 91.06 (+0.18), BIOL: 2.22 (+0.22), DHR: 86.81 (+0.21), HSIC: 143.18 (+0.72)
The Global Dental Device Market to hit $12.7 Billion by 2020 Propelled by a Surge in Oral Diseases and Poor Oral Hygiene: ABMRG
PR Newswire Europe - Tue Dec 09, 7:00AM CST
LONDON and NEW YORK, December 9, 2014 /PRNewswire/ --
SIRO: 91.06 (+0.18), BIOL: 2.22 (+0.22), PDCO: 50.65 (-0.16), SIX: 45.11 (-0.05), DHR: 86.81 (+0.21), HSIC: 143.18 (+0.72)
BIOLASE Launches New EPIC(TM) X diode laser in the United States; Now Dentists Can Delight Their Patients, Faster
PR Newswire - Mon Dec 01, 3:37PM CST
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in lasers, today introduced the EPIC(TM) X diode laser, the company's premier and most complete diode laser for the whole dental team.
BIOL: 2.22 (+0.22)
BIOLASE Introduces a New Commitment to Customer Care, Quality and Innovation at Greater New York Dental Meeting 2014
Business Wire - Fri Nov 28, 11:16AM CST
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced a variety of advances and activities for the upcoming Greater New York Dental Meeting 2014 including the introduction of a new generation EPIC X diode laser, designed to be the premier and complete diode laser for the whole dental team. The Greater New York Dental Meeting, billed as the largest dental congress and exposition in the U.S., will be held from Friday, Nov. 28-Wednesday, Dec. 3, at the Jacob K. Javits Convention Center in New York City. The Exhibits at the meeting will be open from Sunday, Nov. 30-Wednesday Dec. 3.
BIOL: 2.22 (+0.22)
Biolase Announces Management Change
Business Wire - Wed Nov 19, 3:05PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported that Alexander K. Arrow, M.D. has resigned as Chief Medical Officer and will be leaving the Company effective December 3, 2014 to pursue other opportunities.
BIOL: 2.22 (+0.22)
InsiderInsights.com Daily Round Up 11/6/14: Chimerix, Biolase, Barrett Business Services, Ares Capital
InsiderInsights - at Seeking Alpha - Fri Nov 07, 1:06PM CST
72.91 (-0.81), CBG: 34.96 (-0.17), PBFX: 23.40 (+0.95), LLY: 70.56 (+0.03), RL: 135.20 (-0.60), GOOG: 549.01 (+6.08), AER: 43.02 (+0.59), DO: 35.21 (+0.36), TPVG: 14.72 (unch), ARCC: 16.85 (+0.01), CMRX: 40.16 (+0.08), OPK: 13.80 (-0.28), BIOL: 2.22 (+0.22), WRI: 36.17 (-0.34), BBSI: 39.78 (+0.84), CUDA: 35.68 (-1.14), ACGL: 59.95 (+0.36), KPTI: 27.12 (-0.13)
InsiderInsights.com Daily Round Up 11/5/14: ELGX, NS, BIOL, NHF
InsiderInsights - at Seeking Alpha - Thu Nov 06, 3:19AM CST
VR: 42.10 (+0.07), JBHT: 82.88 (+1.09), FCX: 20.29 (+0.82), BBY: 39.11 (-0.08), NS: 61.94 (-0.06), LL: 63.69 (+0.89), ELGX: 14.51 (+0.21), ENFC: 15.40 (+0.12), RCL: 75.56 (-1.19), LMCA: 37.97 (+0.06), SPW: 87.37 (-2.81), OPK: 13.80 (-0.28), BIOL: 2.22 (+0.22), IMI: 1.70 (-0.20), NHF: 11.69 (+0.08), SIX: 45.11 (-0.05), TWTR: 48.50 (+0.55), SCHW: 29.13 (-0.83)
BIOLASE's (BIOL) CEO Jeff Nugent on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 10:01PM CST
BIOL: 2.22 (+0.22)
Biolase beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:26PM CST
BIOL: 2.22 (+0.22)
BIOLASE Reports 2014 Third Quarter Results
Business Wire - Tue Nov 04, 3:07PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported unaudited financial results for the third quarter and nine months ended September 30, 2014.
BIOL: 2.22 (+0.22)
BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement
Business Wire - Tue Nov 04, 12:00PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, announced today that investors including Jack W. Schuler, Oracle Partners, L.P. and other Oracle funds, three funds managed by Camber Capital Management, LLC, Eagle Growth Partners I and II, Birchview Capital L.P., Trellus Partners, LP, CAC, LLC, and certain BIOLASE directors, officers, and employees have agreed to purchase $35 million of unregistered shares of the Company's common stock and warrants to purchase unregistered shares of the Company's common stock in a private placement transaction. Under the terms of the private placement, BIOLASE has agreed to sell an aggregate of 14,162,873 shares of its common stock at the price of $2.39 per share, the closing price quoted on NASDAQ on November 3, 2014. In addition, the investors will receive warrants to purchase up to an aggregate of 9,205,862 shares of BIOLASE(R) common stock at an exercise price of $4.00 per share. The warrants become exercisable six months after the closing of the private placement and have a term of three years from the date of issuance.
BIOL: 2.22 (+0.22)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.09 (+0.30), ITRI: 35.75 (-0.12), AWAY: 29.68 (+0.11), OKE: 47.32 (+0.04), HR: 28.69 (-0.08), NYMT: 7.75 (+0.05), OCLR: 1.55 (+0.09), ENPH: 15.15 (+0.37), ADEP: 6.93 (-0.30), CBSO: 27.51 (+0.58), NSTG: 12.66 (-0.11), MITT: 18.52 (+0.08), CRTO: 40.70 (+0.41), FOXA: 34.72 (+0.31), OKS: 45.47 (+0.07), JMBA: 14.50 (-0.61), IVR: 15.33 (+0.01), CSU: 24.59 (+0.03), MYGN: 34.03 (+0.40), JIVE: 5.34 (+0.02), GAS: 50.07 (+0.27), COUP: 11.06 (-0.07), NRP: 7.86 (-0.45), MOSY: 2.10 (+0.02), COHR: 64.95 (+0.25), DOX: 51.15 (+0.37), CKEC: 29.96 (+0.89), OAS: 16.84 (-0.03), PAYC: 32.37 (-0.71), PCYC: 163.28 (+0.23), AXLL: 47.40 (+0.51), NP: 62.15 (-0.52), BIRT: 6.60 (+0.01), ATVI: 23.11 (+0.17), EXAM: 39.97 (+0.31), P: 15.44 (+0.45), JAZZ: 169.69 (+6.89), PBPB: 13.92 (-0.07), EXEL: 2.48 (+0.20), CERS: 5.53 (+0.08), DVN: 66.47 (+0.69), FEYE: 42.26 (+2.63), CHUY: 22.04 (-0.35), FRGI: 61.80 (-0.33), GHDX: 31.12 (+0.28), PACD: 3.76 (+0.16), BIO: 118.36 (+0.79), BIOL: 2.22 (+0.22), JKHY: 65.78 (+0.52), KAR: 35.64 (-0.03), CDXS: 3.42 (+0.07), MPO: 1.00 (-0.02), FANG: 73.46 (+0.49), CORT: 3.15 (+0.01), CALD: 14.95 (+0.03)
Biolase reports November 4
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:12AM CDT
BIOL: 2.22 (+0.22)
Biolase CFO bids adieu
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:14PM CST
BIOL: 2.22 (+0.22)
BIOLASE Announces Management Change
Business Wire - Fri Feb 06, 3:05PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported that Frederick D. Furry has resigned as Chief Financial Officer, effective January 31, 2015 to pursue other opportunities.
BIOL: 2.22 (+0.22)
UPDATE - Ebola and Other Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 1:43PM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.22 (+0.22)
Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 10:48AM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.22 (+0.22)
Medical Laser Systems - 2014 Global Strategic Business Report
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/q7pvtt/medical_laser) has announced the addition of the "Medical Laser Systems - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Medical Laser Systems in US$ Million by the following Product Segments: - Surgical Lasers - Aesthetic Lasers - Ophthalmic Lasers - Diagnostic Lasers - Therapeutic Lasers - Accessories & Services The report profiles 119 companies including many key and niche players such as: - AngioDynamics, Inc. - Bausch & Lomb Incorporated - BIOLASE, Inc. - Biolitec AG - Cardiogenesis Corporation Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Market Trends And Issues 3. Medical Laser Systems: Product Overview 4. Product Introductions/Approvals 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 119 (including Divisions/Subsidiaries 145) - The United States (70) - Canada (3) - Japan (6) - Europe (53) - France (4) - Germany (22) - The United Kingdom (4) - Italy (7) - Spain (1) - Rest of Europe (15) - Asia-Pacific (Excluding Japan) (10) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/q7...ical_laser
BIOL: 2.22 (+0.22)
Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020
M2 - Tue Dec 16, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcpwzv/global_dental) has announced the addition of the "Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020" report to their offering. The global dental market comprises dental implants, dental prosthesis, dental biomaterials, dental crowns and bridges, dental imaging, dental units and equipment. In the past decade, the market has experienced a swelling expansion due to a surge in the uptake of implants, crowns and cosmetic dentistry. The key factors igniting the market growth include poor oral hygiene, a rise in incidences of oral diseases on the back of a growing elderly population, an improvement in oral care needs of individuals and an increasing disposable income in developing economies. The acceptance and proliferation of technology in terms of dental imaging (3D imaging), design and manufacturing (CAD/CAM) has resulted in better diagnosis, dental designs, patient compliance and a decrease in chair time. Globally, the US is the leading market for dental care devices with its Centers for Medicare and Medicaid Services (CMS) having estimated the demand for dental services in the country to approach $167 billion by 2015. As per The Association of Dental Dealers of Europe (ADEE), in 2011, the European dental market increased by 1.2% in terms of the total turnover for all countries with the number of active dentists increasing slightly by 0.8%. Another key market is the Asia-Pacific region. Japan is a relatively mature market in the APAC region, whereas in developing countries like India and China, rising disposable income of the middle class as well as growing dental-care awareness and consumer acceptance are contributing to market growth. Companies Mentioned - A-Dec Inc. - Biolase Inc. - Danaher Corporation - GC CORPORATION - Henry Schein Inc. - Midmark Corporation - NAKANISHI INC. - Nobel Biocare - Patterson Dental Supply Inc. - Planmeca Oy - Sirona Dental Systems Inc. - Straumann (SIX) - Sybron Dental Specialties Inc. - Young Innovations Inc. For more information visit http://www.researchandmarkets.com/research/tc...bal_dental
SIRO: 91.06 (+0.18), BIOL: 2.22 (+0.22), DHR: 86.81 (+0.21), HSIC: 143.18 (+0.72)
The Global Dental Device Market to hit $12.7 Billion by 2020 Propelled by a Surge in Oral Diseases and Poor Oral Hygiene: ABMRG
PR Newswire Europe - Tue Dec 09, 7:00AM CST
LONDON and NEW YORK, December 9, 2014 /PRNewswire/ --
SIRO: 91.06 (+0.18), BIOL: 2.22 (+0.22), PDCO: 50.65 (-0.16), SIX: 45.11 (-0.05), DHR: 86.81 (+0.21), HSIC: 143.18 (+0.72)
BIOLASE Launches New EPIC(TM) X diode laser in the United States; Now Dentists Can Delight Their Patients, Faster
PR Newswire - Mon Dec 01, 3:37PM CST
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in lasers, today introduced the EPIC(TM) X diode laser, the company's premier and most complete diode laser for the whole dental team.
BIOL: 2.22 (+0.22)
BIOLASE Introduces a New Commitment to Customer Care, Quality and Innovation at Greater New York Dental Meeting 2014
Business Wire - Fri Nov 28, 11:16AM CST
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced a variety of advances and activities for the upcoming Greater New York Dental Meeting 2014 including the introduction of a new generation EPIC X diode laser, designed to be the premier and complete diode laser for the whole dental team. The Greater New York Dental Meeting, billed as the largest dental congress and exposition in the U.S., will be held from Friday, Nov. 28-Wednesday, Dec. 3, at the Jacob K. Javits Convention Center in New York City. The Exhibits at the meeting will be open from Sunday, Nov. 30-Wednesday Dec. 3.
BIOL: 2.22 (+0.22)
Biolase Announces Management Change
Business Wire - Wed Nov 19, 3:05PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported that Alexander K. Arrow, M.D. has resigned as Chief Medical Officer and will be leaving the Company effective December 3, 2014 to pursue other opportunities.
BIOL: 2.22 (+0.22)
InsiderInsights.com Daily Round Up 11/6/14: Chimerix, Biolase, Barrett Business Services, Ares Capital
InsiderInsights - at Seeking Alpha - Fri Nov 07, 1:06PM CST
72.91 (-0.81), CBG: 34.96 (-0.17), PBFX: 23.40 (+0.95), LLY: 70.56 (+0.03), RL: 135.20 (-0.60), GOOG: 549.01 (+6.08), AER: 43.02 (+0.59), DO: 35.21 (+0.36), TPVG: 14.72 (unch), ARCC: 16.85 (+0.01), CMRX: 40.16 (+0.08), OPK: 13.80 (-0.28), BIOL: 2.22 (+0.22), WRI: 36.17 (-0.34), BBSI: 39.78 (+0.84), CUDA: 35.68 (-1.14), ACGL: 59.95 (+0.36), KPTI: 27.12 (-0.13) InsiderInsights.com Daily Round Up 11/5/14: ELGX, NS, BIOL, NHF
InsiderInsights - at Seeking Alpha - Thu Nov 06, 3:19AM CST
VR: 42.10 (+0.07), JBHT: 82.88 (+1.09), FCX: 20.29 (+0.82), BBY: 39.11 (-0.08), NS: 61.94 (-0.06), LL: 63.69 (+0.89), ELGX: 14.51 (+0.21), ENFC: 15.40 (+0.12), RCL: 75.56 (-1.19), LMCA: 37.97 (+0.06), SPW: 87.37 (-2.81), OPK: 13.80 (-0.28), BIOL: 2.22 (+0.22), IMI: 1.70 (-0.20), NHF: 11.69 (+0.08), SIX: 45.11 (-0.05), TWTR: 48.50 (+0.55), SCHW: 29.13 (-0.83)
BIOLASE's (BIOL) CEO Jeff Nugent on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 10:01PM CST
BIOL: 2.22 (+0.22)
Biolase beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:26PM CST
BIOL: 2.22 (+0.22)
BIOLASE Reports 2014 Third Quarter Results
Business Wire - Tue Nov 04, 3:07PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported unaudited financial results for the third quarter and nine months ended September 30, 2014.
BIOL: 2.22 (+0.22)
BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement
Business Wire - Tue Nov 04, 12:00PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, announced today that investors including Jack W. Schuler, Oracle Partners, L.P. and other Oracle funds, three funds managed by Camber Capital Management, LLC, Eagle Growth Partners I and II, Birchview Capital L.P., Trellus Partners, LP, CAC, LLC, and certain BIOLASE directors, officers, and employees have agreed to purchase $35 million of unregistered shares of the Company's common stock and warrants to purchase unregistered shares of the Company's common stock in a private placement transaction. Under the terms of the private placement, BIOLASE has agreed to sell an aggregate of 14,162,873 shares of its common stock at the price of $2.39 per share, the closing price quoted on NASDAQ on November 3, 2014. In addition, the investors will receive warrants to purchase up to an aggregate of 9,205,862 shares of BIOLASE(R) common stock at an exercise price of $4.00 per share. The warrants become exercisable six months after the closing of the private placement and have a term of three years from the date of issuance.
BIOL: 2.22 (+0.22)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.09 (+0.30), ITRI: 35.75 (-0.12), AWAY: 29.68 (+0.11), OKE: 47.32 (+0.04), HR: 28.69 (-0.08), NYMT: 7.75 (+0.05), OCLR: 1.55 (+0.09), ENPH: 15.15 (+0.37), ADEP: 6.93 (-0.30), CBSO: 27.51 (+0.58), NSTG: 12.66 (-0.11), MITT: 18.52 (+0.08), CRTO: 40.70 (+0.41), FOXA: 34.72 (+0.31), OKS: 45.47 (+0.07), JMBA: 14.50 (-0.61), IVR: 15.33 (+0.01), CSU: 24.59 (+0.03), MYGN: 34.03 (+0.40), JIVE: 5.34 (+0.02), GAS: 50.07 (+0.27), COUP: 11.06 (-0.07), NRP: 7.86 (-0.45), MOSY: 2.10 (+0.02), COHR: 64.95 (+0.25), DOX: 51.15 (+0.37), CKEC: 29.96 (+0.89), OAS: 16.84 (-0.03), PAYC: 32.37 (-0.71), PCYC: 163.28 (+0.23), AXLL: 47.40 (+0.51), NP: 62.15 (-0.52), BIRT: 6.60 (+0.01), ATVI: 23.11 (+0.17), EXAM: 39.97 (+0.31), P: 15.44 (+0.45), JAZZ: 169.69 (+6.89), PBPB: 13.92 (-0.07), EXEL: 2.48 (+0.20), CERS: 5.53 (+0.08), DVN: 66.47 (+0.69), FEYE: 42.26 (+2.63), CHUY: 22.04 (-0.35), FRGI: 61.80 (-0.33), GHDX: 31.12 (+0.28), PACD: 3.76 (+0.16), BIO: 118.36 (+0.79), BIOL: 2.22 (+0.22), JKHY: 65.78 (+0.52), KAR: 35.64 (-0.03), CDXS: 3.42 (+0.07), MPO: 1.00 (-0.02), FANG: 73.46 (+0.49), CORT: 3.15 (+0.01), CALD: 14.95 (+0.03)
Biolase reports November 4
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:12AM CDT
BIOL: 2.22 (+0.22)
